-
1
-
-
12344282783
-
Global burden of hypertension: analysis of worldwide data
-
[1] Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
-
(2005)
Lancet
, vol.365
, pp. 217-223
-
-
Kearney, P.M.1
Whelton, M.2
Reynolds, K.3
Muntner, P.4
Whelton, P.K.5
He, J.6
-
2
-
-
77952304253
-
Blood pressure in Canadian adults
-
[2] Wilkins, K., Campbell, N.R., Joffres, M.R., McAlister, F.A., Nichol, M., Quach, S., et al. Blood pressure in Canadian adults. Health Rep. 21 (2010), 37–46.
-
(2010)
Health Rep.
, vol.21
, pp. 37-46
-
-
Wilkins, K.1
Campbell, N.R.2
Joffres, M.R.3
McAlister, F.A.4
Nichol, M.5
Quach, S.6
-
3
-
-
0038460302
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
-
[3] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003), 2560–2572.
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo, J.L.6
-
4
-
-
34547841317
-
Essential hypertension
-
[4] Messerli, F.H., Williams, B., Ritz, E., Essential hypertension. Lancet 370 (2007), 591–603.
-
(2007)
Lancet
, vol.370
, pp. 591-603
-
-
Messerli, F.H.1
Williams, B.2
Ritz, E.3
-
5
-
-
0038690424
-
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000
-
[5] Hajjar, I., Kotchen, T.A., Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290 (2003), 199–206.
-
(2003)
JAMA
, vol.290
, pp. 199-206
-
-
Hajjar, I.1
Kotchen, T.A.2
-
6
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
-
[6] Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
-
(1998)
Lancet
, vol.351
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
Dahlof, B.4
Elmfeldt, D.5
Julius, S.6
-
7
-
-
0034627183
-
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
-
[7] Neal, B., MacMahon, S., Chapman, N., Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000), 1955–1964.
-
(2000)
Lancet
, vol.356
, pp. 1955-1964
-
-
Neal, B.1
MacMahon, S.2
Chapman, N.3
-
8
-
-
0035979589
-
Manipulation of the renin–angiotensin system
-
[8] Givertz, M.M., Manipulation of the renin–angiotensin system. Circulation 104 (2001), E14–E18.
-
(2001)
Circulation
, vol.104
, pp. E14-E18
-
-
Givertz, M.M.1
-
9
-
-
34748859681
-
The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease
-
[9] Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59 (2007), 251–287.
-
(2007)
Pharmacol. Rev.
, vol.59
, pp. 251-287
-
-
Kobori, H.1
Nangaku, M.2
Navar, L.G.3
Nishiyama, A.4
-
10
-
-
0037165229
-
The role of the renin–angiotensin system in the development of cardiovascular disease
-
(discussion 10 A)
-
[10] Unger, T., The role of the renin–angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89 (2002), 3 A–9 A (discussion 10 A).
-
(2002)
Am. J. Cardiol.
, vol.89
, pp. 3 A-9 A
-
-
Unger, T.1
-
11
-
-
0033736285
-
A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension
-
[11] Lacourciere, Y., A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin. Ther. 22 (2000), 1213–1224.
-
(2000)
Clin. Ther.
, vol.22
, pp. 1213-1224
-
-
Lacourciere, Y.1
-
12
-
-
0031932886
-
A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
-
[12] Mimran, A., Ruilope, L., Kerwin, L., Nys, M., Owens, D., Kassler-Taub, K., et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J. Hum. Hypertens. 12 (1998), 203–208.
-
(1998)
J. Hum. Hypertens.
, vol.12
, pp. 203-208
-
-
Mimran, A.1
Ruilope, L.2
Kerwin, L.3
Nys, M.4
Owens, D.5
Kassler-Taub, K.6
-
13
-
-
0034951771
-
Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist
-
[13] Puchler, K., Laeis, P., Stumpe, K.O., Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J. Hypertens. Suppl. 19 (2001), S41–S48.
-
(2001)
J. Hypertens. Suppl.
, vol.19
, pp. S41-S48
-
-
Puchler, K.1
Laeis, P.2
Stumpe, K.O.3
-
14
-
-
14744290689
-
Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals
-
[14] Oparil, S., Silfani, T.N., Walker, J.F., Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am. J. Hypertens. 18 (2005), 287–294.
-
(2005)
Am. J. Hypertens.
, vol.18
, pp. 287-294
-
-
Oparil, S.1
Silfani, T.N.2
Walker, J.F.3
-
15
-
-
79959334521
-
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
-
[15] Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008), e510–e526.
-
(2008)
Circulation
, vol.117
, pp. e510-e526
-
-
Calhoun, D.A.1
Jones, D.2
Textor, S.3
Goff, D.C.4
Murphy, T.P.5
Toto, R.D.6
-
16
-
-
69149107165
-
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
-
(W64)
-
[16] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 (W64).
-
(2009)
Ann. Intern. Med.
, vol.151
, pp. 264-269
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
17
-
-
0026524708
-
Incorporating variations in the quality of individual randomized trials into meta-analysis
-
[17] Detsky, A.S., Naylor, C.D., O'Rourke, K., McGeer, A.J., L'Abbe, K.A., Incorporating variations in the quality of individual randomized trials into meta-analysis. J. Clin. Epidemiol. 45 (1992), 255–265.
-
(1992)
J. Clin. Epidemiol.
, vol.45
, pp. 255-265
-
-
Detsky, A.S.1
Naylor, C.D.2
O'Rourke, K.3
McGeer, A.J.4
L'Abbe, K.A.5
-
18
-
-
0642286336
-
Examining the value and quality of health economic analyses: implications of utilizing the QHES
-
[18] Ofman, J.J., Sullivan, S.D., Neumann, P.J., Chiou, C.F., Henning, J.M., Wade, S.W., et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9 (2003), 53–61.
-
(2003)
J. Manag. Care Pharm.
, vol.9
, pp. 53-61
-
-
Ofman, J.J.1
Sullivan, S.D.2
Neumann, P.J.3
Chiou, C.F.4
Henning, J.M.5
Wade, S.W.6
-
19
-
-
79251590265
-
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
-
[19] Bakris, G.L., Sica, D., Weber, M., White, W.B., Roberts, A., Perez, A., et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens. (Greenwich) 13 (2011), 81–88.
-
(2011)
J. Clin. Hypertens. (Greenwich)
, vol.13
, pp. 81-88
-
-
Bakris, G.L.1
Sica, D.2
Weber, M.3
White, W.B.4
Roberts, A.5
Perez, A.6
-
20
-
-
0034951613
-
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives
-
[20] Ball, K.J., Williams, P.A., Stumpe, K.O., Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J. Hypertens. Suppl. 19 (2001), S49–S56.
-
(2001)
J. Hypertens. Suppl.
, vol.19
, pp. S49-S56
-
-
Ball, K.J.1
Williams, P.A.2
Stumpe, K.O.3
-
21
-
-
33645543047
-
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals
-
[21] Brunner, H.R., Arakawa, K., Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig. 26 (2006), 185–193.
-
(2006)
Clin Drug Investig.
, vol.26
, pp. 185-193
-
-
Brunner, H.R.1
Arakawa, K.2
-
22
-
-
0043172552
-
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension
-
[22] Brunner, H.R., Stumpe, K.O., Januszewicz, A., Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin. Drug Investig. 23 (2003), 419–430.
-
(2003)
Clin. Drug Investig.
, vol.23
, pp. 419-430
-
-
Brunner, H.R.1
Stumpe, K.O.2
Januszewicz, A.3
-
23
-
-
0038042008
-
Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension
-
[23] Chrysant, S.G., Marbury, T.C., Robinson, T.D., Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens., 2003, 425–432.
-
(2003)
J. Hum. Hypertens.
, pp. 425-432
-
-
Chrysant, S.G.1
Marbury, T.C.2
Robinson, T.D.3
-
24
-
-
33746158062
-
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate
-
[24] Chrysant, S.G., Marbury, T.C., Silfani, T.N., Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press. Monit., 2006, 135–141.
-
(2006)
Blood Press. Monit.
, pp. 135-141
-
-
Chrysant, S.G.1
Marbury, T.C.2
Silfani, T.N.3
-
25
-
-
18444416063
-
Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring
-
[25] Destro, M., Scabrosetti, R., Vanasia, A., Mugellini, A., Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv. Ther., 2005, 32–43.
-
(2005)
Adv. Ther.
, pp. 32-43
-
-
Destro, M.1
Scabrosetti, R.2
Vanasia, A.3
Mugellini, A.4
-
26
-
-
84867886614
-
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension
-
[26] Flack, J.M., Graff, A., Li, W., Chavanu, K.J., Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Postgrad. Med. 124 (2012), 59–70.
-
(2012)
Postgrad. Med.
, vol.124
, pp. 59-70
-
-
Flack, J.M.1
Graff, A.2
Li, W.3
Chavanu, K.J.4
-
27
-
-
34247181619
-
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension
-
[27] Giles, T.D., Oparil, S., Silfani, T.N., Wang, A., Walker, J.F., Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J. Clin. Hypertens. (Greenwich) 9 (2007), 187–195.
-
(2007)
J. Clin. Hypertens. (Greenwich)
, vol.9
, pp. 187-195
-
-
Giles, T.D.1
Oparil, S.2
Silfani, T.N.3
Wang, A.4
Walker, J.F.5
-
28
-
-
22544483548
-
Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients
-
[28] Liau, C.S., Lee, C.M., Sheu, S.H., Ueng, K.C., Chien, K.L., Su, T.C., et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients. Clin. Drug Investig., 2005, 473–479.
-
(2005)
Clin. Drug Investig.
, pp. 473-479
-
-
Liau, C.S.1
Lee, C.M.2
Sheu, S.H.3
Ueng, K.C.4
Chien, K.L.5
Su, T.C.6
-
29
-
-
77958463672
-
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study
-
[29] Malacco, E., Omboni, S., Volpe, M., Auteri, A., Zanchetti, A., Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J. Hypertens. 28 (2010), 2342–2350.
-
(2010)
J. Hypertens.
, vol.28
, pp. 2342-2350
-
-
Malacco, E.1
Omboni, S.2
Volpe, M.3
Auteri, A.4
Zanchetti, A.5
-
30
-
-
34748894914
-
Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension
-
[30] Mallion, J.M., Heagerty, A., Laeis, P., Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J. Hypertens. 25 (2007), 2168–2177.
-
(2007)
J. Hypertens.
, vol.25
, pp. 2168-2177
-
-
Mallion, J.M.1
Heagerty, A.2
Laeis, P.3
-
31
-
-
85027903203
-
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension
-
[31] Mallion, J.M., Omboni, S., Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. J. Hypertens., 2010, e45.
-
(2010)
J. Hypertens.
, pp. e45
-
-
Mallion, J.M.1
Omboni, S.2
-
32
-
-
0034760610
-
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
-
(318)
-
[32] Oparil, S., Williams, D., Chrysant, S.G., Marbury, T.C., Neutel, J., Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (Greenwich) 3 (2001), 283–291 (318).
-
(2001)
J. Clin. Hypertens. (Greenwich)
, vol.3
, pp. 283-291
-
-
Oparil, S.1
Williams, D.2
Chrysant, S.G.3
Marbury, T.C.4
Neutel, J.5
-
33
-
-
84866512636
-
Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension
-
[33] Punzi, H.A., Lewin, A., Li, W., Chavanu, K.J., Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension. Adv. Ther. 29 (2012), 524–537.
-
(2012)
Adv. Ther.
, vol.29
, pp. 524-537
-
-
Punzi, H.A.1
Lewin, A.2
Li, W.3
Chavanu, K.J.4
-
34
-
-
12744269551
-
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan
-
[34] Smith, D.H., Dubiel, R., Jones, M., Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am. J. Cardiovasc. Drugs 5 (2005), 41–50.
-
(2005)
Am. J. Cardiovasc. Drugs
, vol.5
, pp. 41-50
-
-
Smith, D.H.1
Dubiel, R.2
Jones, M.3
-
35
-
-
0036105846
-
Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs
-
[35] Stumpe, K.O., Ludwig, M., Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J. Hum. Hypertens. 16:Suppl. 2 (2002), S24–S28.
-
(2002)
J. Hum. Hypertens.
, vol.16
, pp. S24-S28
-
-
Stumpe, K.O.1
Ludwig, M.2
-
36
-
-
79952275464
-
A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension
-
[36] Weir, M.R., Punzi, H.A., Flack, J.M., Stoakes, K.A., Chavanu, K.J., Li, W., et al. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgrad. Med. 123 (2011), 80–87.
-
(2011)
Postgrad. Med.
, vol.123
, pp. 80-87
-
-
Weir, M.R.1
Punzi, H.A.2
Flack, J.M.3
Stoakes, K.A.4
Chavanu, K.J.5
Li, W.6
-
37
-
-
79953239152
-
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
-
[37] White, W.B., Weber, M.A., Sica, D., Bakris, G.L., Perez, A., Cao, C., et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57 (2011), 413–420.
-
(2011)
Hypertension
, vol.57
, pp. 413-420
-
-
White, W.B.1
Weber, M.A.2
Sica, D.3
Bakris, G.L.4
Perez, A.5
Cao, C.6
-
38
-
-
34547308715
-
Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study
-
[38] Barrios, V., Boccanelli, A., Ewald, S., Girerd, X., Heagerty, A., Krzesinski, J.M., et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin. Drug Investig. 27 (2007), 545–558.
-
(2007)
Clin. Drug Investig.
, vol.27
, pp. 545-558
-
-
Barrios, V.1
Boccanelli, A.2
Ewald, S.3
Girerd, X.4
Heagerty, A.5
Krzesinski, J.M.6
-
39
-
-
67650302856
-
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study
-
[39] Barrios, V., Brommer, P., Haag, U., Calderon, A., Escobar, C., Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29 (2009), 427–439.
-
(2009)
Clin. Drug Investig.
, vol.29
, pp. 427-439
-
-
Barrios, V.1
Brommer, P.2
Haag, U.3
Calderon, A.4
Escobar, C.5
-
40
-
-
74049152360
-
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
-
[40] Barrios, V., Escobar, C., Calderon, A., Bohm, M., Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Vasc. Health Risk Manag. 5 (2009), 723–729.
-
(2009)
Vasc. Health Risk Manag.
, vol.5
, pp. 723-729
-
-
Barrios, V.1
Escobar, C.2
Calderon, A.3
Bohm, M.4
-
41
-
-
84920908365
-
Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone
-
[41] Bilo, G., Koch, W., Hoshide, S., Parati, G., Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone. Hypertens. Res. 37 (2014), 836–844.
-
(2014)
Hypertens. Res.
, vol.37
, pp. 836-844
-
-
Bilo, G.1
Koch, W.2
Hoshide, S.3
Parati, G.4
-
42
-
-
70349151351
-
Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study
-
[42] Chrysant, S.G., Chavanu, K.J., Xu, J., Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am. J.Cardiovasc. Drugs, 2009, 241–251.
-
(2009)
Am. J.Cardiovasc. Drugs
, pp. 241-251
-
-
Chrysant, S.G.1
Chavanu, K.J.2
Xu, J.3
-
43
-
-
43549100189
-
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
-
[43] Chrysant, S.G., Melino, M., Karki, S., Lee, J., Heyrman, R., The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther., 2008, 587–604.
-
(2008)
Clin. Ther.
, pp. 587-604
-
-
Chrysant, S.G.1
Melino, M.2
Karki, S.3
Lee, J.4
Heyrman, R.5
-
44
-
-
70349973807
-
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
-
[44] Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J., Heyrman, R., Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens. (Greenwich), 2009, 475–482.
-
(2009)
J. Clin. Hypertens. (Greenwich)
, pp. 475-482
-
-
Chrysant, S.G.1
Oparil, S.2
Melino, M.3
Karki, S.4
Lee, J.5
Heyrman, R.6
-
45
-
-
1442299290
-
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
-
[45] Chrysant, S.G., Weber, M.A., Wang, A.C., Hinman, D.J., Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens., 2004, 252–259.
-
(2004)
Am. J. Hypertens.
, pp. 252-259
-
-
Chrysant, S.G.1
Weber, M.A.2
Wang, A.C.3
Hinman, D.J.4
-
46
-
-
84882977181
-
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies
-
[46] Derosa, G., Cicero, A.F., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., et al. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opin. Drug Saf. 12 (2013), 621–629.
-
(2013)
Expert Opin. Drug Saf.
, vol.12
, pp. 621-629
-
-
Derosa, G.1
Cicero, A.F.2
Carbone, A.3
Querci, F.4
Fogari, E.5
D'Angelo, A.6
-
47
-
-
84881660487
-
Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension
-
[47] Ding, S., Liu, J., Fu, Q., Zheng, Y., Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension. Arch. Gerontol. Geriatr., 2013, 423–427.
-
(2013)
Arch. Gerontol. Geriatr.
, pp. 423-427
-
-
Ding, S.1
Liu, J.2
Fu, Q.3
Zheng, Y.4
-
48
-
-
77954626007
-
Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study
-
[48] Fogari, R., Taddei, S., Holm-Bentzen, M., Baszak, J., Melani, L., Schumacher, K., Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin. Drug Investig. 30 (2010), 581–597.
-
(2010)
Clin. Drug Investig.
, vol.30
, pp. 581-597
-
-
Fogari, R.1
Taddei, S.2
Holm-Bentzen, M.3
Baszak, J.4
Melani, L.5
Schumacher, K.6
-
49
-
-
33845602177
-
Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy
-
[49] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Destro, M., Rinaldi, A., et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv. Ther., 2006, 680–695.
-
(2006)
Adv. Ther.
, pp. 680-695
-
-
Fogari, R.1
Zoppi, A.2
Mugellini, A.3
Preti, P.4
Destro, M.5
Rinaldi, A.6
-
50
-
-
41249095681
-
Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study
-
[50] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Destro, M., Rinaldi, A., et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr. Ther. Res. Clin. Exp., 2008, 1–15.
-
(2008)
Curr. Ther. Res. Clin. Exp.
, pp. 1-15
-
-
Fogari, R.1
Zoppi, A.2
Mugellini, A.3
Preti, P.4
Destro, M.5
Rinaldi, A.6
-
51
-
-
84858631158
-
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients
-
[51] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Perrone, T., Maffioli, P., et al. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert. Opin. Pharmacother. 13 (2012), 629–636.
-
(2012)
Expert. Opin. Pharmacother.
, vol.13
, pp. 629-636
-
-
Fogari, R.1
Zoppi, A.2
Mugellini, A.3
Preti, P.4
Perrone, T.5
Maffioli, P.6
-
52
-
-
83055176358
-
24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy
-
[52] Izzo, J.L. Jr., Chrysant, S.G., Kereiakes, D.J., Littlejohn Iii, T., Oparil, S., Melino, M., et al. 24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J. Clin. Hypertens. (Greenwich) 13 (2011), 873–880.
-
(2011)
J. Clin. Hypertens. (Greenwich)
, vol.13
, pp. 873-880
-
-
Izzo, J.L.1
Chrysant, S.G.2
Kereiakes, D.J.3
Littlejohn Iii, T.4
Oparil, S.5
Melino, M.6
-
53
-
-
84862810814
-
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension
-
[53] Kereiakes, D.J., Chrysant, S.G., Izzo, J.L. Jr., Littlejohn, T. 3rd, Oparil, S., Melino, M., et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J. Clin. Hypertens. (Greenwich) 14 (2012), 149–157.
-
(2012)
J. Clin. Hypertens. (Greenwich)
, vol.14
, pp. 149-157
-
-
Kereiakes, D.J.1
Chrysant, S.G.2
Izzo, J.L.3
Littlejohn, T.4
Oparil, S.5
Melino, M.6
-
54
-
-
35448989395
-
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate
-
[54] Kereiakes, D.J., Neutel, J.M., Punzi, H.A., Xu, J., Lipka, L.J., Dubiel, R., Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am. J. Cardiovasc. Drugs 7 (2007), 361–372.
-
(2007)
Am. J. Cardiovasc. Drugs
, vol.7
, pp. 361-372
-
-
Kereiakes, D.J.1
Neutel, J.M.2
Punzi, H.A.3
Xu, J.4
Lipka, L.J.5
Dubiel, R.6
-
55
-
-
84876956841
-
Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension
-
[55] Lin, T.H., Tsai, C.D., Pan, J.P., Hou, C.J., Hsia, C.H., Tsai, J.P., et al. Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. Kaohsiung J. Med. Sci. 29 (2013), 265–270.
-
(2013)
Kaohsiung J. Med. Sci.
, vol.29
, pp. 265-270
-
-
Lin, T.H.1
Tsai, C.D.2
Pan, J.P.3
Hou, C.J.4
Hsia, C.H.5
Tsai, J.P.6
-
56
-
-
67549116889
-
Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study
-
[56] Mourad, J.J., Jeune, S., Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig., 2009, 419–425.
-
(2009)
Clin. Drug Investig.
, pp. 419-425
-
-
Mourad, J.J.1
Jeune, S.2
-
57
-
-
73849138948
-
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study
-
[57] Ogihara, T., Saruta, T., Shimada, K., Kuramoto, K., A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertens. Res. 32 (2009), 1148–1154.
-
(2009)
Hypertens. Res.
, vol.32
, pp. 1148-1154
-
-
Ogihara, T.1
Saruta, T.2
Shimada, K.3
Kuramoto, K.4
-
58
-
-
74349114056
-
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use
-
[58] Oparil, S., Lee, J., Karki, S., Melino, M., Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J. Cardiovasc. Pharmacol. 54 (2009), 427–436.
-
(2009)
J. Cardiovasc. Pharmacol.
, vol.54
, pp. 427-436
-
-
Oparil, S.1
Lee, J.2
Karki, S.3
Melino, M.4
-
59
-
-
77955251021
-
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study
-
[59] Oparil, S., Melino, M., Lee, J., Fernandez, V., Heyrman, R., Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32 (2010), 1252–1269.
-
(2010)
Clin. Ther.
, vol.32
, pp. 1252-1269
-
-
Oparil, S.1
Melino, M.2
Lee, J.3
Fernandez, V.4
Heyrman, R.5
-
60
-
-
84977642194
-
A comparative study of efficacy & safety of aliskiren as an add on therapy to olmesartan versus olmesartan monotherapy in patients with hypertension
-
[60] Rajkumar, J., Kaushal, J., Aggarwal, H.K., A comparative study of efficacy & safety of aliskiren as an add on therapy to olmesartan versus olmesartan monotherapy in patients with hypertension. Indo Global J. Pharm. Sci., 2014, 103–112.
-
(2014)
Indo Global J. Pharm. Sci.
, pp. 103-112
-
-
Rajkumar, J.1
Kaushal, J.2
Aggarwal, H.K.3
-
61
-
-
80052036781
-
Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension
-
[61] Rump, L.C., Girerd, X., Sellin, L., Stegbauer, J., Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J. Hum. Hypertens. 25 (2011), 565–574.
-
(2011)
J. Hum. Hypertens.
, vol.25
, pp. 565-574
-
-
Rump, L.C.1
Girerd, X.2
Sellin, L.3
Stegbauer, J.4
-
62
-
-
29244443966
-
Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension
-
[62] Sellin, L., Stegbauer, J., Laeis, P., Rump, L.C., Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J. Hypertens. 23 (2005), 2083–2092.
-
(2005)
J. Hypertens.
, vol.23
, pp. 2083-2092
-
-
Sellin, L.1
Stegbauer, J.2
Laeis, P.3
Rump, L.C.4
-
63
-
-
77954783076
-
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study
-
[63] Shimada, K., Ogihara, T., Saruta, T., Kuramoto, K., Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin. Ther. 32 (2010), 861–881.
-
(2010)
Clin. Ther.
, vol.32
, pp. 861-881
-
-
Shimada, K.1
Ogihara, T.2
Saruta, T.3
Kuramoto, K.4
-
64
-
-
57449086215
-
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study
-
[64] Volpe, M., Brommer, P., Haag, U., Miele, C., Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29 (2009), 11–25.
-
(2009)
Clin. Drug Investig.
, vol.29
, pp. 11-25
-
-
Volpe, M.1
Brommer, P.2
Haag, U.3
Miele, C.4
-
65
-
-
84865487190
-
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination
-
[65] Volpe, M., Christian Rump, L., Ammentorp, B., Laeis, P., Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin. Drug Investig. 32 (2012), 649–664.
-
(2012)
Clin. Drug Investig.
, vol.32
, pp. 649-664
-
-
Volpe, M.1
Christian Rump, L.2
Ammentorp, B.3
Laeis, P.4
-
66
-
-
67549119235
-
Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study
-
[66] Volpe, M., Miele, C., Haag, U., Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29 (2009), 381–391.
-
(2009)
Clin. Drug Investig.
, vol.29
, pp. 381-391
-
-
Volpe, M.1
Miele, C.2
Haag, U.3
-
67
-
-
84903773938
-
Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension
-
[67] Volpe, M., Sierra, A., Ammentorp, B., Laeis, P., Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv. Ther., 2014, 561–574.
-
(2014)
Adv. Ther.
, pp. 561-574
-
-
Volpe, M.1
Sierra, A.2
Ammentorp, B.3
Laeis, P.4
-
68
-
-
84937574988
-
Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy
-
[68] Zhu, J.R., Zhang, S.Y., Gao, P.J., Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch. Pharm. Res. 37 (2014), 1588–1598.
-
(2014)
Arch. Pharm. Res.
, vol.37
, pp. 1588-1598
-
-
Zhu, J.R.1
Zhang, S.Y.2
Gao, P.J.3
-
69
-
-
84880015206
-
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
[69] Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31 (2013), 1281–1357.
-
(2013)
J. Hypertens.
, vol.31
, pp. 1281-1357
-
-
Mancia, G.1
Fagard, R.2
Narkiewicz, K.3
Redon, J.4
Zanchetti, A.5
Bohm, M.6
-
70
-
-
0036672238
-
A population-based European cohort study of persistence in newly diagnosed hypertensive patients
-
[70] Hasford, J., Mimran, A., Simons, W.R., A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J. Hum. Hypertens. 16 (2002), 569–575.
-
(2002)
J. Hum. Hypertens.
, vol.16
, pp. 569-575
-
-
Hasford, J.1
Mimran, A.2
Simons, W.R.3
-
71
-
-
77149122711
-
Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
-
[71] Boersma, C., Voors, A.A., Visser, S.T., de Jong-van den Berg, L.T., Postma, M.J., Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am. J. Cardiovasc. Drugs. 10 (2010), 49–54.
-
(2010)
Am. J. Cardiovasc. Drugs.
, vol.10
, pp. 49-54
-
-
Boersma, C.1
Voors, A.A.2
Visser, S.T.3
de Jong-van den Berg, L.T.4
Postma, M.J.5
-
72
-
-
0037232826
-
Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan
-
[72] Simons, W.R., Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. PharmacoEconomics 21 (2003), 61–74.
-
(2003)
PharmacoEconomics
, vol.21
, pp. 61-74
-
-
Simons, W.R.1
-
73
-
-
55549114333
-
Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model
-
[73] Saito, I., Kobayashi, M., Matsushita, Y., Mori, A., Kawasugi, K., Saruta, T., Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens. Res. 31 (2008), 1373–1383.
-
(2008)
Hypertens. Res.
, vol.31
, pp. 1373-1383
-
-
Saito, I.1
Kobayashi, M.2
Matsushita, Y.3
Mori, A.4
Kawasugi, K.5
Saruta, T.6
-
74
-
-
77952533332
-
Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension
-
[74] Miller, L.A., Wade, R., Dai, D., Cziraky, M.J., Ramaswamy, K., Panjabi, S., Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr. Med. Res. Opin. 26 (2010), 1307–1320.
-
(2010)
Curr. Med. Res. Opin.
, vol.26
, pp. 1307-1320
-
-
Miller, L.A.1
Wade, R.2
Dai, D.3
Cziraky, M.J.4
Ramaswamy, K.5
Panjabi, S.6
-
75
-
-
80052753077
-
Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens
-
[75] Belsey, J.D., Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens. J. Med. Econ. 14 (2011), 553–561.
-
(2011)
J. Med. Econ.
, vol.14
, pp. 553-561
-
-
Belsey, J.D.1
-
76
-
-
84866326463
-
Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis
-
[76] Wang, L., Zhao, J.W., Liu, B., Shi, D., Zou, Z., Shi, X.Y., Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am. J. Cardiovasc. Drugs. 12 (2012), 335–344.
-
(2012)
Am. J. Cardiovasc. Drugs.
, vol.12
, pp. 335-344
-
-
Wang, L.1
Zhao, J.W.2
Liu, B.3
Shi, D.4
Zou, Z.5
Shi, X.Y.6
-
77
-
-
16644396876
-
Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies
-
[77] Ram, C.V., Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J. Clin. Hypertens. (Greenwich) 6 (2004), 569–577.
-
(2004)
J. Clin. Hypertens. (Greenwich)
, vol.6
, pp. 569-577
-
-
Ram, C.V.1
-
78
-
-
84873272608
-
Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
-
[78] Basile, J., Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integr Blood Press Control, 3, 2010, 91–104.
-
(2010)
Integr Blood Press Control
, vol.3
, pp. 91-104
-
-
Basile, J.1
-
79
-
-
79551541604
-
Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension
-
[79] Deeks, E.S., Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs, 2011, 209–220.
-
(2011)
Drugs
, pp. 209-220
-
-
Deeks, E.S.1
-
80
-
-
33846931415
-
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
-
[80] Greathouse, M., Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc. Health Risk Manag. 2 (2006), 401–409.
-
(2006)
Vasc. Health Risk Manag.
, vol.2
, pp. 401-409
-
-
Greathouse, M.1
-
81
-
-
79961196737
-
Olmesartan/amlodipine: a review of its use in the management of hypertension
-
[81] Kreutz, R., Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc. Health Risk Manag. 7 (2011), 183–192.
-
(2011)
Vasc. Health Risk Manag.
, vol.7
, pp. 183-192
-
-
Kreutz, R.1
-
82
-
-
84866497260
-
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
-
[82] Punzi, H.A., Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integr Blood Press Control, 4, 2011, 73–83.
-
(2011)
Integr Blood Press Control
, vol.4
, pp. 73-83
-
-
Punzi, H.A.1
-
83
-
-
60249093548
-
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
-
[83] Ruilope, L.M., Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. Vasc. Health Risk Manag. 4 (2008), 1237–1248.
-
(2008)
Vasc. Health Risk Manag.
, vol.4
, pp. 1237-1248
-
-
Ruilope, L.M.1
-
84
-
-
66049134201
-
Olmesartan medoxomil/amlodipine
-
[84] Sanford, M., Keam, S.J., Olmesartan medoxomil/amlodipine. Drugs 69 (2009), 717–729.
-
(2009)
Drugs
, vol.69
, pp. 717-729
-
-
Sanford, M.1
Keam, S.J.2
-
85
-
-
44949171907
-
Olmesartan medoxomil: a review of its use in the management of hypertension
-
[85] Scott, L.J., McCormack, P.L., Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68 (2008), 1239–1272.
-
(2008)
Drugs
, vol.68
, pp. 1239-1272
-
-
Scott, L.J.1
McCormack, P.L.2
|